Literature DB >> 2881762

Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites.

D J Tweedie, M D Burke.   

Abstract

This study extends an investigation of the metabolism of the beta-carbolines, harmine and harmol, by untreated, phenobarbitone-induced, or 3-methylcholanthrene (MC)-induced mouse liver microsomes to identify two MC-inducible metabolites of harmine and to quantitate their rates of formation using 3H-labeled substrate. An HPLC system was devised to separate harmine and its metabolites. The major metabolite with MC-induced microsomes was identified by mass spectroscopy and by NMR to be 6-hydroxy-7-methoxyharman and was produced at an initial reaction rate of 11 nmol/min/mg of microsomal protein (27-fold induction). The other novel metabolite, 3- or 4-hydroxy-7-methoxyharman (the position of the hydroxyl group could not be definitively assigned by NMR) was produced at an initial reaction rate of 3.8 nmol/min/mg of microsomal protein (32-fold induction) which was similar to the rate of formation of the other metabolite, harmol, determined previously. All three metabolites were further metabolized to unidentified metabolites. Protein binding of [3H]harmine and [3H]harmol was measured and shown to be metabolism dependent. It was also noted that the alkali conditions used for optimal extraction stimulated the protein binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881762

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Metabolism of the aldose reductase inhibitor ALO1567 in man.

Authors:  Y H Park; J E Hudson; R C Barker; B M York; R K Brazzell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

2.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.

Authors:  Julia Sacher; Sylvain Houle; Jun Parkes; Pablo Rusjan; Sandra Sagrati; Alan A Wilson; Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2011-11       Impact factor: 6.186

4.  Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats.

Authors:  Y Guan; E D Louis; W Zheng
Journal:  J Toxicol Environ Health A       Date:  2001-12-21

Review 5.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

6.  Sequence specific binding of beta carboline alkaloid harmalol with deoxyribonucleotides: binding heterogeneity, conformational, thermodynamic and cytotoxic aspects.

Authors:  Sarita Sarkar; Prateek Pandya; Kakali Bhadra
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

7.  Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy.

Authors:  Marie Spies; Gregory M James; Chrysoula Vraka; Cécile Philippe; Marius Hienert; Gregor Gryglewski; Arkadiusz Komorowski; Alexander Kautzky; Leo Silberbauer; Verena Pichler; Georg S Kranz; Lukas Nics; Theresa Balber; Pia Baldinger-Melich; Thomas Vanicek; Benjamin Spurny; Edda Winkler-Pjrek; Wolfgang Wadsak; Markus Mitterhauser; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger; Dietmar Winkler
Journal:  Transl Psychiatry       Date:  2018-09-21       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.